Abstract 1820P
Background
Cardiovascular (CV) events remain a significant cause of mortality amongst men with advanced and metastatic prostate cancer (PCa). The introduction of novel androgen receptor signalling inhibitors (ARSI) has transformed the treatment landscape of PCa in recent years, however their impact on CV toxicity remains unclear. We aimed to assess the CV effects of ARSI treatment in combination with standard of care (SOC) in advanced and metastatic PCa.
Methods
Systematic search of PubMed, SCOPUS, Web of Science, EMBASE and Clinicaltrials.gov were performed to identify randomized controlled trials (RCTs) comparing the addition of ARSI agents (Enzalutamide, Abiraterone, Apalutamide and Darolutamide) with SOC in treatment of non-metastatic and metastatic PCa, across both hormone-sensitive and castrate resistant settings. Outcomes of interest included: CV events defined by CV event grade (primary outcome), hypertension, acute coronary syndrome (ACS), cardiac dysrhythmia, CV death, cerebrovascular event, and venous thromboembolism (secondary outcomes).
Results
A total of 22 studies (n=22,967) were eligible for inclusion. ARSI therapy increased risk of any grade CV event (RR 1.72, 1.49-2.00, p<0.0001) and grade ≥ 3 CV events (RR 1.98 [1.58-2.48] p<0.0001). ARSI therapy also resulted in an increase in grade ≥ 3 hypertension (RR 2.02 [1.62-2.53] p<0.0001), ACS (RR 2.00 [1.46-2.74] p<0.0001), grade ≥3 cardiac dysrhythmia (RR 1.64 [1.23-2.19] p=0.0007), CV related death (RR 1.88 [1.22-2.89] p=0.004) and cerebrovascular events (RR 1.76[1.33-2.34] p<0.0001) across all PCa settings. Subgroup analysis demonstrated increased risk of all CV events and grade ≥3 across the disease spectrum (RR for all CV events: non-metastatic hormone sensitive PCa 2.20 [1.4-3.47], p<0.0007; metastatic hormone sensitive PCa 1.69 [1.39-2.06], p<0.0001; metastatic castrate resistant PCa 1.53 [1.36-1.71], p<0.0001).
Conclusions
There is compelling evidence indicating a significantly increased risk of all and high-grade CV events in men treated with ARSIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Genitourinary Cancer Research Group, University of Manchester, Manchester, United Kingdom.
Funding
Has not received any funding.
Disclosure
N.W. Clarke: Non-Financial Interests, Institutional, Other, Investigator on PRONOUNCE Trial. All other authors have declared no conflicts of interest.
Resources from the same session
1960P - Clinical outcomes of the patients with alveolar soft part sarcoma developed brain metastasis
Presenter: Yu Toda
Session: Poster session 15
1961P - Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center
Presenter: Khomsit Thongthammachat
Session: Poster session 15
1963P - Comprehensive profiling of chordoma reveals tumor microenvironment subtypes and unique molecular findings
Presenter: Marina Voropaeva
Session: Poster session 15
1964P - Biomimetics of three-dimensional (3D) osteosarcoma (OS) models: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 15
1965P - Transcriptional analysis of immune microenvironment of chordomas of the skull base and mobile spine
Presenter: Jason Roszik
Session: Poster session 15
1966P - Extending the interval of denosumab treatment for unresectable giant cell tumor of bone
Presenter: Toshiyuki Kunisada
Session: Poster session 15
1967P - A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIb classic osteosarcoma of the extremity
Presenter: Fan Tang
Session: Poster session 15
1968P - Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1969P - Intratumoral immune infiltrates in chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 15
1970P - Metastatic chondrosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15